We are using cookies to give you the best experience on our site. Cookies are files stored in your browser and are used by most websites to help personalise your web experience. By continuing to use our website without changing the settings, you are agreeing to our use of cookies.

Share
  • Facebook
  • Twitter
  • Linked In
  • Google+
back top
ICRS / ON Basic Scientist Fellowship 2018

1300 members from 70 countries Join ICRS

News

BEDFORD, Mass.–Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced that regulatory authorities in Australia granted approval to MONOVISC®, Anika’s single injection viscosupplement for the treatment of pain associated with osteoarthritis of all synovial joints, including the hip and knee. 

Anika Announces Regulatory Approval for MONOVISC® in Australia

Anika Announces Regulatory Approval for MONOVISC® in Australia

20/10/2017

Clinical trial evidence shows that ACI can improve the symptoms of articular cartilage defects of the knee. There is evidence that it is likely to be more successful in people who haven’t had any previous knee repair surgery, and in people who have very little osteoarthritic damage in the knee. But, it is unclear how well ACI works in the long term compared with microfracture, the most commonly used alternative treatment.

NICE (National Institute for Clinical Excellence) Guidance on ACI

NICE (National Institute for Clinical Excellence) Guidance on ACI

06/10/2017

It is an enormous pleasure to welcome over 150 participants from 31 countries and from all 4 corners of the world. We do have confirmed participants from Austria, Bangladesh, Belgium, Brazil, Canada, Chile, Croatia, Denmark, Ecuador, Estonia, France, Germany, Greece, India, Ireland, Italy, South Korea, Malaysia, Mexico, Netherlands, Oman, Poland, Qatar, Russian Federation, Slovenia, Spain, Switzerland, Turkey, UAE, United Kingdom & United States of America – a truly international event!

ICRS Focus Meeting Osteoarthritis in the Athlete

ICRS Focus Meeting Osteoarthritis in the Athlete

08/09/2017

Vericel (Nasdaq: VCEL), a specialty biologics company with three approved cellular therapy products on the market might still be underappreciated by investors after its recent run?

Vericel (VCEL): Revenue Growth Fueled by Three Cellular Therapies

Vericel (VCEL): Revenue Growth Fueled by Three Cellular Therapies

01/09/2017